AI systems for scientific discovery

I build the reasoning layer of drug-discovery programs — from evidence to decision

↓ What I do

What I do

Acting under uncertainty

There are no guarantees in science, nor in life, yet you still have to make choices. That's the challenge I build for - systems that help you make the best decisions possible given incomplete information. My work lives at the reasoning layer: turning complex, insufficient evidence into decision-grade substrate.

I'm a software engineer with 25 years of shipping, but philosophy is my first love. I trained in it alongside neuroscience, and I bring a systems-level, first-principles way of thinking to the design of scientific tools and programs.

Raising a child with a rare disease teaches you many things, not the least that if the answers don't exist yet, you have to find them yourself. So I'm building a decision-intelligence platform for running translational research programs — and proving it on a real one: I founded the CURE5 Foundation to accelerate therapies for CDKL5 Epilepsy, and I run its portfolio across AI-driven drug repurposing, cortical-organoid screening, iPSC development and small-molecule discovery, with Harvard, Boston Children's Hospital, BrainStorm Therapeutics, Unravel Biosciences and other labs.

Earlier I shipped FDA-cleared software for seizure detection and built real-time data systems now permanently installed at the 9/11 Memorial Museum. I also work with early-stage biotech and health-AI companies as a fractional CTO, helping them design their translational programs and architect the AI systems that will run them.

Lisbon & New YorkEN · SV · ES · PTRare-disease drug discovery · CDKL5

Selected work

  1. In development · 2025 → present

    A decision platform for drug discovery

    Founder & builder

    A decision-intelligence platform I'm building to run translational drug-discovery programs end to end — turning scattered biology (variants, mechanisms, screens, literature) into the small set of decisions that actually move a program forward. Multi-scale gene atlases and a structured knowledge layer, paired with AI agents that read the evidence and surface the next critical decision. In private use today, running a live rare-disease portfolio.

    Private beta — walkthrough on request
  2. 2023 → present

    CURE5 Foundation

    Founder & operator

    Running a translational research portfolio in AI-driven drug discovery, cortical-organoid screening, iPSC development and custom small-molecule therapeutics for CDKL5 Epilepsy. Partners: Harvard, Boston Children's Hospital, BrainStorm Therapeutics, Unravel Biosciences.

    Visit
  3. 2025 → present

    Jimini Health

    Senior AI Engineer

    Full-stack engineering on a clinician-supervised AI behavioral-health platform ($25M-backed; advisory board includes DeepMind and Yale leaders) — building the patient-facing surface of an LLM product where model output meets clinical-safety review.

    Visit
  4. Prior

    FDA-cleared seizure detection software

    Engineering lead

    Clinical software for real-time seizure detection, developed through 510(k) clearance. Regulated, high-consequence shipping in a domain where accuracy directly affects patient care. Case study on request.

    Case study
  5. Permanent installation

    9/11 Memorial Museum — real-time visualization

    Design & engineering, with Elevated Studio

    A permanent installation at the National September 11 Memorial & Museum depicting the ongoing impact of 9/11 through real-time data and archival material.

    Watch
  6. 2001 → present

    Elevated Studio

    Founder

    A boutique studio for scientific and medical visualization I founded in 2001. Selected work for the New York Times, Samsung, ConsenSys, ARoS Art Museum and the XQ Institute.

    Visit

Working with me

A small number of engagements per year, with biotech and pharma teams that need someone who can architect the AI systems and translate between computation, wet-lab science and regulatory reality.

Typical engagements

Get in touch

Talks & media

Upcoming · Sep 14–15, 2026 · Barcelona

Navigating Rare Disease Research: Data, Ethics & AI in Europe

Speaker — “Introduction to AI and drug repurposing.” EURORDIS Open Academy.

Upcoming · Nov 18, 2026 · San Francisco

GATC 2026 — Genetic Agency Technology Conference

Speaker. Hosted by Dyno Therapeutics.

Watch · CURE5

CURE5 Knowledge Engine

An AI tool that answers questions from the CDKL5 research literature, with citations.

Watch · CURE5

CURE5 Foundation @ IEC2025

At the International League Against Epilepsy congress in Lisbon.

Listen

On AI & CDKL5 research

The CDKL5 in Color podcast, episode 35.